Transcript Title and contents - Rijksuniversiteit Groningen

Multi-Drug Tuberculosis in the Netherlands
Personalised treatment and outcome
Richard van Altena
Publication of this thesis was financially supported by
Afdeling Longziekten en Tuberculose UMCG
KNCV Tuberculosis Foundation
Stichting Beatrixoord Noord-Nederland
UMCG Centrum voor Revalidatie
UMCG Graduate School of Medical Sciences
VvAwT (Association of physicians working in tuberculosis control)
Cover
Layout
Printed by
ISBN
ISBN
C(Kees).J.P. Thijn, symbolisch-surrealistisch schilde – www.thijnhof.nl
Ridderprint BV, the Netherlands – www.ridderprint.nl
Ridderprint BV, the Netherlands – www.ridderprint.nl
978-94-6299-433-1
978-94-6299-434-8 (electronic version)
© Richard van Altena 2016
Copyright of the published articles is with the corresponding journal or otherwise with the author. No part of this
publication may be produced, stored in a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing from the author or the copyright-owning journal.
Multi-Drug Tuberculosis in the Netherlands
Personalised treatment and outcome
Proefschrift
Ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. E. Sterken
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
dinsdag 15 november 2016 om 11:00 uur
door
Richard van Altena
geboren op 17 december 1947
te Haarlem
Promotores
Prof. dr. T.S. van der Werf
Prof. dr. H.A.M. Kerstjens
Copromotor
Dr. J.W.C. Alffenaar
Beoordelingscommissie
Prof. dr. G.B. Migliori
Prof. dr. F.G.J. Cobelens
Prof. dr. B.N.M. Sinha
Contents
1
Introduction
2
Immunology
a Immunology in tuberculosis: challenges in monitoring of disease activity and
identifying correlates of protection.
3
Individualised MDR-TB treatment
a Multidrug-resistant tuberculosis: long-term treatment outcome in the
18
43
44
56
58
Aminoglycosides
a Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in
patients with tuberculosis.
b Reduced chance of hearing loss associated with Therapeutic Drug Monitoring
of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis.
c Limited sampling strategies for therapeutic drug monitoring of amikacin and
kanamycin in patients with multidrug-resistant tuberculosis.
79
e
5
17
Netherlands.
Antituberculosis-drug resistance
Multidrug resistant tuberculosis
Highly successful treatment outcome of multidrug-resistant tuberculosis in
the Netherlands, 2000-2009
Shorter treatment for multi-drug resistant tuberculosis: the good, the bad
and the ugly
b
c
d
4
7
60
74
80
92
110
Ertapenem
a Pharmacokinetics of ertapenem in patients with multidrug-resistant
tuberculosis.
b Pharmacokinetic Modeling and Limited Sampling Strategies based on healthy
volunteers for Monitoring of Ertapenem in MDR-TB patients.
125
6
Discussion & Future Perspectives
153
7
Appendices
Nederlandse samenvatting
Lijst met afkortingen / list with abbreviations
Dankwoord
Curriculum vitae
List of publications
126
137
173
189
191
201
205